FSP1-Targeted Ferroptosis Induction: A Novel Therapeutic Strategy Validated in Dual Landmark Nature Studies

November 5, 2025, top international academic journal《Nature》Two groundbreaking studies were published in the same issue, focusing on a so-called"Ferroptosis Suppressor Protein 1"(FSP1, ferroptosis suppressor protein 1) protein. Two independent studies from Harvard University and New York University have confirmed this in metastatic melanoma and lung adenocarcinoma, respectively:Blocking FSP1 can effectively trigger cancer cell death, opening up a brand-new pathway for cancer treatment.

To understand the importance of FSP1, it is first necessary to understand ferroptosis, a unique form of cell death.Ferroptosisis a type ofDriven by Excessive Lipid Peroxidation in Cell Membranesa form of cell death. When iron ions accumulate within cells and generate large amounts of reactive oxygen species (ROS), these highly reactive molecules attack and oxidize lipids in the cell membrane, ultimately leading to the collapse of membrane structure and cell death. While this should serve as a natural defense mechanism for the body to eliminate abnormal cells, cancer cells have evolved sophisticated counterstrategies—by upregulating antioxidant proteins such as FSP1, they create a “protective umbrella” to evade ferroptosis.

Harvard Study: Environment-Dependent Vulnerabilities in Metastatic Melanoma

Professor Jessalyn Ubellacker’s team at the Harvard T.H. Chan School of Public Health has directed its research focus toward metastatic melanoma, particularly cancer cells that have spread to the lymph nodes. This is a critically important area of investigation.Because metastatic disease—rather than the primary tumor—is the true culprit responsible for the majority of cancer-related deaths.

The uniqueness of this study lies in its approach fromIn Vivo Environmentin vivo, rather than traditional petri dish experiments. The research team used a melanoma tumor model in mouse lymph nodes and unexpectedly discovered a shocking phenomenon:In the specialized microenvironment of lymph nodes, melanoma cells become highly dependent on FSP1 to resist ferroptosis, making FSP1 their "key survival switch."

(Source: Nature)

More surprisingly, when researchers delivered the FSP1 inhibitor directly to lymph node tumors, tumor growth decreased dramatically; however, testing the same drug in petri dishes had minimal impact on cancer cell death. This stark discrepancy between in vivo and in vitro effects reveals a critical issue:The antioxidant defense system utilized by cancer cells is heavily dependent on their tissue microenvironment.

Dr. Mario Palma, the first author, pointed out:“Rather than attempting to kill every tumor cell in the same way, we can exploit the vulnerabilities that emerge when cancer spreads to specific organs.”This provides a completely new perspective for precision medicine.

NYU Study: Ferroptosis Defense Mechanisms in Lung Adenocarcinoma

A research team led by Professor Thales Y. Papagiannakopoulos at NYU Langone Health has achieved a significant breakthrough in the study of lung adenocarcinoma (LUAD). Lung adenocarcinoma is the most common type of lung cancer among non-smokers, accounting for approximately40%, and lung cancer is the leading cause of cancer-related deaths worldwide.

This study systematically validated the role of FSP1 in lung cancer through a dual approach combining genetic engineering and pharmacological experiments. The research team first genetically modified mice by deleting the FSP1 gene in lung cancer cells, resulting inThere was a significant increase in cancer cell death, and the tumor shrank markedly.

(Source: Nature)

More encouragingly, treatment of mice bearing lung tumors with the potent FSP1 inhibitor icFSP1 reduced tumor growth byUp to 80%,Overall survival was significantly improved. This result fully demonstrates the therapeutic potential of FSP1 inhibitors.

The study also revealed the unique advantages of FSP1 compared to another ferroptosis inhibitor, GPX4 (which has been studied for many years): FSP1 plays a greater role in blocking ferroptosis in lung cancer but has a smaller impact on normal cell function, which meansPotential side effects may be fewer. In addition, the study foundElevated FSP1 Levels Are Associated with Poor Survival in Patients with Human Lung Adenocarcinoma, which provides new biomarkers for clinical prognosis assessment.

First author Katherine Wu emphasized:“This is the first test of a drug that blocks ferroptosis inhibition, highlighting the importance of this process for cancer cell survival.”

Although these two studies focus on different types of cancer—One is metastatic melanoma, and the other is lung adenocarcinoma.—Yet together, they underscore the broad prospects of FSP1 as an anticancer therapeutic target. From multiple perspectives, FSP1 has demonstrated substantial potential to emerge as a next-generation target for anticancer drug development.

Broad Applicability Across Cancer Types

Significant efficacy of FSP1 inhibitors was observed in two studies involving entirely different cancer types. Although melanoma and lung cancer differ vastly in their origin, biological characteristics, and microenvironment, FSP1 plays a critical anti-ferroptotic role in both, strongly suggesting that FSP1 may be a pan-cancer therapeutic target.

This finding has significant clinical implications:FSP1 inhibitors may be applicable to a broader range of solid tumors, such as pancreatic cancer and breast cancer.Based on this characteristic, the clinical development of FSP1 inhibitors can be tested simultaneously across multiple cancer types with high FSP1 expression, thereby accelerating the drug development process.

Significant Technological Advantages

Compared with the traditional GPX4 target, FSP1 has three significant technical advantages: first,Higher Tumor Specificity, FSP1 plays a more significant role in cancer cells while having a relatively minor effect in normal cells, which implies a wider therapeutic window and potentially fewer side effects; secondlyEnvironmental Adaptability Targeting, the Harvard team’s findings suggest that more precise treatment regimens can be designed for specific metastatic sites (such as lymph nodes, lungs, and liver), thereby achieving true"Precision Environmental Medicine"。

Clear Pathway for Clinical Translation

New York University Research Finds,High FSP1 Expression Is Associated with Poor Survival in Patients with Lung Adenocarcinoma, which provides a clear biomarker for clinical trials. By detecting FSP1 expression levels, it is possible to identify the patient population most likely to benefit from the treatment, thereby improving the success rate of clinical trials.

Meanwhile, FSP1 inhibitors are expected to be used in combination with existing immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors), chemotherapy agents, or targeted therapies to produce synergistic effects.Ferroptosis Induction May Enhance Immune System Recognition and Clearance of Tumors, offering new possibilities for combination therapy strategies.

A Leap in Technological Maturity

Notably, the novel FSP1 inhibitors used in both studies were jointly developed by the laboratory of Dr. Marcus Conrad at the Helmholtz Center Munich in Germany and the laboratory of Dr. James Olzmann at the University of California, Berkeley. These inhibitors have demonstrated robust in vivo activity and specificity, laying a solid foundation for the rapid advancement into clinical trials.

The Harvard team’s research also underscores a key point:Understanding Cancer Cannot Rely Solely on Petri Dish Experiments.The behavior of cancer cells within the body is profoundly influenced by the tissue microenvironment, this"Environmental Dependence"This not only determines their vulnerability but also provides a novel entry point for precision therapy.

Katherine Wu stated in her research outlook:“Our goal is to translate these findings from the laboratory into novel clinical therapies for cancer patients.”Professor Jessalyn Ubellacker stated:“These findings lay the foundation for potential new therapeutic strategies to slow cancer progression by targeting ferroptosis defense mechanisms.”